Scientific basis for cancer prevention. Intermediate cancer markers
- PMID: 8334673
- DOI: 10.1002/1097-0142(19930801)72:3+<978::aid-cncr2820721305>3.0.co;2-t
Scientific basis for cancer prevention. Intermediate cancer markers
Abstract
Promising cancer clinical trials results involving the disruption of early stages of cancer with intervention agents such as tamoxifen or retinoids have led to significant new research interest in developing preventative strategy for the control of epithelial cancers. Key to the efficient progress in this field is a clear understanding of the complex biology of the early stages of cancerization that proceed on the epithelial surface. Systematic analysis of the biology of strategic targets such as growth factors is one approach to this problem. Gastrin-releasing peptide is an autocrine growth factor for certain types of lung cancer cells. Mechanisms involved in the production and activation of this peptide are discussed as an example of how rational approaches to neutralization of cancer promotion biology can be achieved. The tools to monitor the success of this type of intervention also emerge from the understanding of the biology of growth factors, and intermediate end point markers that determine the presence or effects of a growth factor are attractive candidates for evaluation. Additional biologic tools reflecting the early stages of the cancer process need to be validated for use in serially evaluating the status of the relevant epithelium so that the ongoing success of a cancer intervention procedure can be established. Through this type of translational research, important applications of molecular biology may greatly improve the success of preventative strategies for cancer control.
Similar articles
-
The correct dose: pharmacologically guided end point for anti-growth factor therapy.Cancer Res. 1992 May 1;52(9 Suppl):2743s-2746s. Cancer Res. 1992. PMID: 1314137
-
Candidate biomarkers for application as intermediate end points of lung carcinogenesis.J Cell Biochem Suppl. 1992;16G:183-6. doi: 10.1002/jcb.240501131. J Cell Biochem Suppl. 1992. PMID: 1469899 Review.
-
Biology and chemoprevention of lung cancer.Chest. 1998 Jan;113(1 Suppl):40S-45S. doi: 10.1378/chest.113.1_supplement.40s. Chest. 1998. PMID: 9438689 Review.
-
The retinoids and cancer prevention mechanisms.Oncologist. 2000;5(5):361-8. doi: 10.1634/theoncologist.5-5-361. Oncologist. 2000. PMID: 11040271 Review.
-
Gastrin-releasing peptide and other autocrine growth factors in lung cancer: pathogenetic and treatment implications.Important Adv Oncol. 1988:55-64. Important Adv Oncol. 1988. PMID: 3042610 Review. No abstract available.
Cited by
-
Beyond bench and bedside: disentangling the concept of translational research.Health Care Anal. 2015 Mar;23(1):32-49. doi: 10.1007/s10728-012-0236-x. Health Care Anal. 2015. PMID: 23248053 Free PMC article.
-
Major milestones in translational oncology.BMC Med. 2016 Jul 28;14(1):110. doi: 10.1186/s12916-016-0654-y. BMC Med. 2016. PMID: 27469586 Free PMC article.
-
Translational Research in Oncology: Implications for Palliative Care.Indian J Palliat Care. 2017 Oct-Dec;23(4):462-467. doi: 10.4103/IJPC.IJPC_88_17. Indian J Palliat Care. 2017. PMID: 29123356 Free PMC article.
-
Enhancing quality of retrieval through concept edit history.AMIA Annu Symp Proc. 2003;2003:279-83. AMIA Annu Symp Proc. 2003. PMID: 14728178 Free PMC article.
-
Translational Research in Endocrinology.J Clin Transl Endocrinol. 2014 Jan 21;1(1):e1. doi: 10.1016/j.jcte.2013.11.001. eCollection 2014 Mar. J Clin Transl Endocrinol. 2014. PMID: 29159079 Free PMC article. No abstract available.